George Dunbar, current CEO of Isto Technologies, will serve as CEO of Isto Biologics. "We are grateful for the support of Thompson Street Capital Partners and excited to lead Isto Biologics into the future," said Mr. Dunbar. "The integration of Isto and Arteriocyte presents an opportunity to leverage our combined expertise to establish a strong position in an ever-changing market and better serve our physician partners, as they work to grow their practice and meet the demands of value-based healthcare."
Isto Biologics' expanded, best-in-class product portfolio will feature Arteriocyte's market-leading MAGELLAN® Autologous Platelet Separator and Isto's bone-growth and cell-therapy products, including InQu® Bone Graft Extender & Substitute; Influx®, a natural bone-graft material; and CellPoint®, a concentrated bone marrow aspirate system.
About Isto Biologics
Isto Biologics was formed in 2016 when St. Louis-based Isto Technologies and Arteriocyte Medical Systems Inc. of Hopkinton, Massachusetts, integrated under the Isto Holdings umbrella. Isto Biologics is focused on offering evidence-based solutions for bone regeneration and cell therapy to help improve patient outcomes. The company's best-in-class product offerings include Arteriocyte's market-leading MAGELLAN® Autologous Platelet Separator and Isto's bone-growth and cell-therapy products including InQu® Bone Graft Extender & Substitute; Influx®, a natural bone-graft material; and CellPoint®, a concentrated bone marrow aspirate system.
For more information, visit istobiologics.com.
Director of Marketing
Logo - http://photos.prnewswire.com/prnh/20161019/430449LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/isto-and-arteriocyte-join-forces-to-form-leading-biologics-player-isto-biologics-300347724.html
SOURCE Isto Biologics